Xtant Medical Holdings, Inc.
Xtant Medical Holdings, Inc. Fundamental Analysis
Xtant Medical Holdings, Inc. (XTNT) shows weak financial fundamentals with a PE ratio of 45.96, profit margin of 1.32%, and ROE of 3.77%. The company generates $0.1B in annual revenue with strong year-over-year growth of 28.44%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 48.4/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze XTNT's fundamental strength across five key dimensions:
Efficiency Score
WeakXTNT struggles to generate sufficient returns from assets.
Valuation Score
ModerateXTNT shows balanced valuation metrics.
Growth Score
ModerateXTNT shows steady but slowing expansion.
Financial Health Score
ExcellentXTNT maintains a strong and stable balance sheet.
Profitability Score
WeakXTNT struggles to sustain strong margins.
Key Financial Metrics
Is XTNT Expensive or Cheap?
P/E Ratio
XTNT trades at 45.96 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, XTNT's PEG of 0.34 indicates potential undervaluation.
Price to Book
The market values Xtant Medical Holdings, Inc. at 1.60 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 5.39 times EBITDA. This is generally considered low.
How Well Does XTNT Make Money?
Net Profit Margin
For every $100 in sales, Xtant Medical Holdings, Inc. keeps $1.32 as profit after all expenses.
Operating Margin
Core operations generate 4.77 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $3.77 in profit for every $100 of shareholder equity.
ROA
Xtant Medical Holdings, Inc. generates $1.65 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Xtant Medical Holdings, Inc. generates limited operating cash flow of $7.87M, signaling weaker underlying cash strength.
Free Cash Flow
Xtant Medical Holdings, Inc. produces free cash flow of $5.20M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.04 in free cash annually.
FCF Yield
XTNT converts 6.15% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
45.96
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.34
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.60
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.61
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.64
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.21
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.04
vs 25 benchmark
ROA
Return on assets percentage
0.02
vs 25 benchmark
ROCE
Return on capital employed
0.09
vs 25 benchmark
How XTNT Stacks Against Its Sector Peers
| Metric | XTNT Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 45.96 | 27.86 | Worse (Expensive) |
| ROE | 3.77% | 763.00% | Weak |
| Net Margin | 1.32% | -20450.00% (disorted) | Weak |
| Debt/Equity | 0.64 | 0.31 | Weak (High Leverage) |
| Current Ratio | 2.21 | 4.50 | Strong Liquidity |
| ROA | 1.65% | -14743.00% (disorted) | Weak |
XTNT outperforms its industry in 1 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Xtant Medical Holdings, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
-82.14%
Industry Style: Defensive, Growth, Innovation
DecliningEPS CAGR
80.29%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
-183.67%
Industry Style: Defensive, Growth, Innovation
Declining